Arndt Vogel: Radiofrequency Ablation vs Stereotactic Body Radiotherapy for Recurrent Small HCC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:
“Radiofrequency Ablation vs Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma ≤5 cm.
- Open-Label Trial, 166 patients
- mPFS tim 37.6 vs 27.6 mo
- 2-year OS 97.6 vs 93.9%
- Both treatments highly effective, better LPFS with SBRT.”
Authors: Mian Xi, Zhoutian Yang, Li Hu, Yizhen Fu, Dandan Hu, Zhongguo Zhou, Mengzhong Liu, Jing Zhao, Jingxian Shen, Qiaoqiao Li, Baoqing Chen, Li Xu, Aiping Fang, Minshan Chen, Shiliang Liu, Yaojun Zhang
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023